COMPARISON
Cagrilintide vs Lixisenatide
6 attributes held for at least one of the two. 6 differ. Each value carries the register it came from and the date that register was read.
Answer
Cagrilintide is authorised or registered in 0 and Lixisenatide in 8 of the 10 registers read. Cagrilintide: highest phase Phase 3 (17 phase 3 trials, 0 with posted results). Lixisenatide: No trial states a phase. 0 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Cagrilintide | Lixisenatide | |
|---|---|---|
| Registered trials differs | 66 clinicaltrials.gov · 2026-10-03 | 75 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | Not checked no record of "fdaLabel" for cagrilintide | FDA-approved: Soliqua 100/33 openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation differs | Nothing on record ema read 2026-08-31 | Authorised ema · 2026-10-03 |
| EU authorised on differs | Not checked no record of "authorisedOn" for cagrilintide | 2017-01-11 ema · 2026-10-03 |
| EU withdrawn on differs | Not checked no record of "withdrawnOn" for cagrilintide | 2024-08-27 ema · 2026-10-03 |
| ATC code differs | Not checked no record of "atcCode" for cagrilintide | A10AE54 ema · 2026-10-03 |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Cagrilintide | placebo | Lixisenatide | placebo |
|---|---|---|---|---|
| Nausea | 29.0% | 14.8% | 24.8% | 6.5% |
| Diarrhoea | 16.1% | 6.6% | 10.1% | 8.1% |
| Vomiting | 9.7% | 1.6% | 10.3% | 2.6% |
| COVID-19 | 16.1% | 13.1% | - | - |
| Constipation | 16.1% | 13.1% | - | - |
| Fatigue | 9.7% | 1.6% | - | - |
| Gastrooesophageal reflux disease | 9.7% | 1.6% | - | - |
| Back pain | 6.5% | 3.3% | - | - |
| Eructation | 6.5% | 0.0% | - | - |
| Gastroenteritis | 6.5% | 6.6% | - | - |
| Hypoglycaemia | - | - | 18.4% | 16.4% |
| Headache | - | - | 9.6% | 6.8% |
| Nasopharyngitis | - | - | 9.1% | 9.0% |
| Dizziness | - | - | 8.3% | 6.3% |
| Hypertension | - | - | 4.6% | 4.9% |
| Influenza | - | - | 4.4% | 2.4% |
| Angina pectoris | - | - | 4.3% | 5.5% |
Trial register Cagrilintide: 1 placebo-controlled trials; Lixisenatide: 11. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Cagrilintide side effects · Lixisenatide side effects
LEGAL STATUS
Approval in each country read
| Country | Cagrilintide | Lixisenatide | Register |
|---|---|---|---|
| United States | Not on the register | FDA-approved | Regulator FDA |
| European Union | Not on the register | Authorised | Regulator EMA |
| United Kingdom | Not on the register | Not on the register | Regulator MHRA |
| Canada | Not on the register | Authorised | Regulator Health Canada |
| Australia | Status unknown | Status unknown | TGA |
| Switzerland | Not on the register | Authorised | Regulator Swissmedic |
| Brazil | Not on the register | Registado | Regulator ANVISA |
| Serbia | Not on the register | Authorised | Regulator ALIMS |
| Singapore | Not on the register | Registered | Regulator HSA |
| Turkey | Not on the register | Ruhsatli | Regulator TITCK |
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.